These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 18048813)
1. Moving beyond guidelines to improve the quality of care for men with prostate cancer. Saigal CS J Clin Oncol; 2007 Dec; 25(34):5348-9. PubMed ID: 18048813 [No Abstract] [Full Text] [Related]
2. Prostate cancer in Spain: from guidelines to clinical practice. Alcaraz A; Burgos FJ; Cózar JM; Gómez-Veiga F; Morote J; Solsona E; Unda M; Carballido J BJU Int; 2011 Jul; 108(1):61-6. PubMed ID: 21223474 [TBL] [Abstract][Full Text] [Related]
3. Quality of care in prostate cancer: important to start and too important to stop here. Talcott JA J Clin Oncol; 2003 May; 21(10):1902-3. PubMed ID: 12743141 [No Abstract] [Full Text] [Related]
4. Current status and prospects of androgen depletion therapy for prostate cancer. Akaza H Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787 [TBL] [Abstract][Full Text] [Related]
5. Variations in the use of prostate cancer staging tests: results from one NCCN Institution. Bennett CL; Yang T; Nadler R Oncology (Williston Park); 1997 Nov; 11(11A):155-7. PubMed ID: 9430186 [TBL] [Abstract][Full Text] [Related]
7. [Practice guideline 'Prostate cancer: diagnosis and treatment']. de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308 [TBL] [Abstract][Full Text] [Related]
8. [Prostate cancer in Scandinavia. Variations in practice and attitude to radical treatment]. Heggestad T; Jonsson PM; Danneskiold-Samsøe B; Leisti S Nord Med; 1993; 108(4):104-6. PubMed ID: 8479895 [TBL] [Abstract][Full Text] [Related]
9. FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part I: intact prostate. Lehman M; Hayden AJ; Martin JM; Christie D; Kneebone AB; Sidhom M; Skala M; Tai KH J Med Imaging Radiat Oncol; 2014 Apr; 58(2):257-65. PubMed ID: 24304822 [TBL] [Abstract][Full Text] [Related]
10. Development of indicators of the quality of radiotherapy for localized prostate cancer. Danielson B; Brundage M; Pearcey R; Bass B; Pickles T; Bahary JP; Foley K; Mackillop W Radiother Oncol; 2011 Apr; 99(1):29-36. PubMed ID: 21458094 [TBL] [Abstract][Full Text] [Related]
11. Modern trends in urology. Andersson L Ann Chir Gynaecol; 1989; 78(3):238-41. PubMed ID: 2589814 [No Abstract] [Full Text] [Related]
12. Current Opinion in Urology. Prostate cancer. Current world literature. Curr Opin Urol; 2009 May; 19(3):327-34. PubMed ID: 19363350 [No Abstract] [Full Text] [Related]
13. "Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer. Dale W J Clin Oncol; 2009 Jul; 27(21):3420-2. PubMed ID: 19506150 [No Abstract] [Full Text] [Related]
14. Variations in quality of care for men with early-stage prostate cancer. Spencer BA; Miller DC; Litwin MS; Ritchey JD; Stewart AK; Dunn RL; Gay EG; Sandler HM; Wei JT J Clin Oncol; 2008 Aug; 26(22):3735-42. PubMed ID: 18669460 [TBL] [Abstract][Full Text] [Related]
15. Androgen suppression therapy and prostate cancer: balancing the harms and the benefits. Oefelein MG Cancer; 2008 Dec; 113(12):3275-8. PubMed ID: 18988289 [No Abstract] [Full Text] [Related]
16. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Agarwal PK; Sadetsky N; Konety BR; Resnick MI; Carroll PR; Cancer; 2008 Jan; 112(2):307-14. PubMed ID: 18050294 [TBL] [Abstract][Full Text] [Related]
18. Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy. Palma D; Pickles T Cancer; 2008 May; 112(10):2322-3; author reply 2323. PubMed ID: 18327816 [No Abstract] [Full Text] [Related]
19. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged? Singer EA; Golijanin DJ; Messing EM Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy. Palma D; Tyldesley S; Pickles T; Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]